Looking beyond the hype: AI/ML’s role in advancing cell & gene therapies
Artificial intelligence is everywhere—but how much is it actually impacting cell and gene therapy development? In this expert-led session, we move past the buzzwords to examine real-world AI/ML implementations already underway across the advanced therapies sector. From operational data pipelines to predictive analytics in manufacturing, discover where innovation is happening, and what challenges still stand in the way.
)
In this webinar, industry leaders from Cellectis, the Cell Therapy Manufacturability Program and Alliance for Artificial Intelligence in Healthcare cut through the noise to explore the current and practical use of AI/ML in cell and gene therapy development. From identifying what data needs to be captured to enable operational AI/ML pipelines, to examining live use cases already demonstrating value, this session offers a realistic picture of AI’s evolving role in the sector.
When:
Thursday, July 17, 2025 · 4:00 p.m. London (GMT +1:00)
Agenda:
- The current landscape of AI/ML adoption in cell and gene therapies
- The types of data needed to drive meaningful AI/ML outcomes
- Active projects building real-world AI/ML use cases
- What the future may realistically hold for AI/ML in manufacturing and analytics
Speakers:
David Sourdive, Ph.D.
Co-founder, Executive Vice President, CMC & Manufacturing at Cellectis
Kat Kozyrytska
Founder of Cell Therapy Manufacturability Program
Elaine Hamm
Executive Director at Alliance for Artificial Intelligence in Healthcare